Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

312 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial.
Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E; N-MOmentum study investigators. Cree BAC, et al. Among authors: madani s. Lancet. 2019 Oct 12;394(10206):1352-1363. doi: 10.1016/S0140-6736(19)31817-3. Epub 2019 Sep 5. Lancet. 2019. PMID: 31495497 Clinical Trial.
Placebo-controlled study in neuromyelitis optica-Ethical and design considerations.
Cree BA, Bennett JL, Sheehan M, Cohen J, Hartung HP, Aktas O, Kim HJ, Paul F, Pittock S, Weinshenker B, Wingerchuk D, Fujihara K, Cutter G, Patra K, Flor A, Barron G, Madani S, Ratchford JN, Katz E. Cree BA, et al. Among authors: madani s. Mult Scler. 2016 Jun;22(7):862-72. doi: 10.1177/1352458515620934. Epub 2015 Dec 14. Mult Scler. 2016. PMID: 26666258 Free PMC article. Clinical Trial.
Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
Agius MA, Klodowska-Duda G, Maciejowski M, Potemkowski A, Li J, Patra K, Wesley J, Madani S, Barron G, Katz E, Flor A. Agius MA, et al. Among authors: madani s. Mult Scler. 2019 Feb;25(2):235-245. doi: 10.1177/1352458517740641. Epub 2017 Nov 16. Mult Scler. 2019. PMID: 29143550 Free PMC article. Clinical Trial.
Value of Radiomics Features Extracted from Baseline CT Images in Predicting Overall Survival in Patients with Non-Surgical Pancreatic Ductal Adenocarcinoma: Incorporation of a Radiomics Score to a Multi-Parametric Nomogram to Predict One-Year Overall Survival.
Madani SP, Mirza-Aghazadeh-Attari M, Mohseni A, Afyouni S, Zandieh G, Shahbazian H, Borhani A, Yazdani I, Laheru D, Pawlik TM, Kamel IR. Madani SP, et al. J Gastrointest Surg. 2024 Nov 9:101882. doi: 10.1016/j.gassur.2024.101882. Online ahead of print. J Gastrointest Surg. 2024. PMID: 39528002
Two metabolic enzymes, LDH and FASN, serum levels in Bladder cancer patients.
Fattahi MJ, Sedaghat F, Haghshenas MR, Ariafar A, Shiravani Z, Malekzadeh M, Madani S. Fattahi MJ, et al. Among authors: madani s. Caspian J Intern Med. 2024 Aug 30;15(4):636-643. doi: 10.22088/cjim.15.4.636. eCollection 2024 Fall. Caspian J Intern Med. 2024. PMID: 39359453 Free PMC article.
Evaluating the Effectiveness of the COPD Assessment Test (CAT) in Screening for Chronic Obstructive Pulmonary Disease.
Al Wachami N, Boumendil K, Arraji M, Iderdar Y, Mourajid Y, Ghosne N, Benmoussa A, Khalis M, Korrida A, Laamiri FZ, Lajane H, Louerdi ML, El Madani S, Chahboune M. Al Wachami N, et al. Among authors: el madani s. Int J Chron Obstruct Pulmon Dis. 2024 Jul 11;19:1623-1633. doi: 10.2147/COPD.S460649. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 39011121 Free PMC article.
312 results